[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649406":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":44,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":62,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":75,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Istanbul Saglik Bilimleri University","OTHER",[8,12,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":10},"SGLT2 Group",null,"Type 2 Diabetes Mellitus patients receiving only SGLT2 inhibitor treatment will be included in this group. Serum NRG4 levels and metabolic parameters will be evaluated.",{"label":13,"type":10,"description":14,"interventionNames":10},"Non-SGLT2 OAD Group","Type 2 Diabetes Mellitus patients receiving metformin with or without insulin therapy, but not receiving SGLT2 inhibitors, will be included in this group.",{"label":16,"type":10,"description":17,"interventionNames":10},"SGLT2 Combination Group","Type 2 Diabetes Mellitus patients receiving metformin with or without insulin together with SGLT2 inhibitor therapy will be included in this group.",{"label":19,"type":10,"description":20,"interventionNames":10},"Newly Diagnosed DM Group","Newly diagnosed treatment-naive Type 2 Diabetes Mellitus patients who have not received any antidiabetic therapy will be included in this group.",{"label":22,"type":10,"description":23,"interventionNames":10},"Healthy Control Group","Age-matched participants without Diabetes Mellitus diagnosis will be included as healthy controls for comparison of serum NRG4 levels and metabolic parameters.",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"GÜLDEN ANATACA","CONTACT","+905059284244","ganataca@yahoo.com",[31],{"facility":32,"status":10,"city":33,"state":10,"zip":10,"country":34,"countryCode":10,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Kanuni Sultan Süleyman Training and Research Hospital","Istanbul","Turkey (Türkiye)",{"type":36,"coordinates":37},"Point",[38,39],28.94966,41.01384,{"lat":39,"lon":38},[42],{"name":43,"role":27,"phone":28,"phoneExt":10,"email":29},"gülden ANATACA",{"type":45,"investigatorFullName":26,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","specialist","100649406","evaluation-of-neuregulin-4-nrg4-levels-in-obese-and-non-obese-patients-with-type-2-diabetes-mellitus-100649406",false,"NCT07734558","Evaluation of Neuregulin-4 (NRG4) Levels in Obese and Non-Obese Patients With Type 2 Diabetes Mellitus","Evaluation of the Relationship Between Serum Neuregulin-4 (NRG4) Levels, Obesity Status, and Antidiabetic Treatment Regimens in Patients With Type 2 Diabetes Mellitus: A Prospective Observational Study","NRG4-T2DM","Inclusion Criteria:\n\n* Age 18-65 years\n* Newly diagnosed treatment-naïve T2DM\n* T2DM treated for at least 6 months\n* BMI \\>30 kg\u002Fm²\n* BMI \\\u003C25 kg\u002Fm²\n* No pregnancy\n* No breastfeeding\n* No active infection\n* No inflammatory disease\n* Written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Pregnancy\n* Breastfeeding\n* Active infection\n* Rheumatologic disease\n* Refusal to participate",true,"ALL","18 Years","65 Years",{"count":60,"type":61},125,"ESTIMATED","1 Day","OBSERVATIONAL","This prospective observational study aims to evaluate serum Neuregulin-4 (NRG4) concentrations in obese and non-obese adults with Type 2 Diabetes Mellitus (T2DM) and to investigate their association with obesity status, insulin resistance, and different antidiabetic treatment regimens. Participants will be categorized into five predefined groups according to obesity status and treatment regimen, including SGLT2 inhibitor users, non-SGLT2 oral antidiabetic therapy users, SGLT2 combination therapy users, newly diagnosed treatment-naïve patients, and healthy controls. Clinical, anthropometric, and laboratory parameters including fasting plasma glucose, HbA1c, estimated glomerular filtration rate (eGFR), body mass index, waist circumference, waist-to-hip ratio, and serum NRG4 concentrations will be evaluated. The study aims to determine whether NRG4 may serve as a novel biomarker reflecting metabolic status and treatment response in patients with T2DM.",[66,67,68],"Type 2 Diabetes Mellitus (T2DM)","Obesity Type 2 Diabetes Mellitus","Insulin Resistance",[70,71,72,73,74],"Neuregulin-4","NRG4","Type 2 Diabetes Mellitus","Obesity","Adipokine","NOT_YET_RECRUITING","2026-07-27",{"date":78,"type":79},"2026-07-29","ACTUAL",{"date":81,"type":61},"2026-06",{"date":83,"type":61},"2026-12-30",{"name":26,"class":6},1]